Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...

As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

Lupin Ltd acquires Huminsulin from Eli Lilly to expand diabetes portfolio, offering a range of human insulin options.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Through Dec. 20, the FDA approved 50 brand new medicines, defined as proteins, small molecules, or other chemicals this year.

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...